FindTrial
Sign In

Neoadjuvant immunochemotherapy

DRUG6 trials

Sponsors

Henan Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Zhongshan Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University

Conditions

Cervical CancersChemoradiotherapyEsophageal CancerEsophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Lung CancerNeoadjuvant ImmunochemotherapyNeoadjuvant Treatment

Phase 2

Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
RecruitingNCT07003620
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCervical Cancers
Start: 2025-06-29End: 2028-11-30Target: 34Updated: 2025-06-17
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
RecruitingNCT07086469
Sun Yat-sen UniversityChemoradiotherapy, Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy +2
Start: 2025-07-20End: 2029-07-19Target: 69Updated: 2025-11-17

Phase 3

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
RecruitingNCT04280822
Henan Cancer HospitalEsophageal Cancer, Neoadjuvant Treatment, Surgery +1
Start: 2020-04-21End: 2028-03-02Target: 400Updated: 2022-10-04

Unknown Phase

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC
RecruitingNCT05974007
Cancer Institute and Hospital, Chinese Academy of Medical SciencesNon-Small Cell Lung Cancer
Start: 2022-01-01End: 2026-06-01Target: 1500Updated: 2023-08-03
Neoadjuvant Immunochemotherapy for Lung Cancer
CompletedNCT06023797
Shanghai Zhongshan HospitalLung Cancer
Start: 2017-01-31End: 2023-07-31Updated: 2023-09-05
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
CompletedNCT07236320
Yongtao HanEsophageal Squamous Cell Carcinoma (ESCC)
Start: 2018-03-01End: 2025-02-28Updated: 2025-11-19

Related Papers

An interim analysis of phase III study on neoadjuvant chemotherapy versus perioperative toripalimab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).
Journal of Clinical Oncology2025-05-28
Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
2024-02-1015 citations
Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1).
2021-11-0166 citations
A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)
Annals of Translational Medicine2021-01-0139 citations